Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc. 2011

Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
Cancer Research Programme, IMIM (Institut de Recerca Hospital del Mar), Dr Aiguader 88, Barcelona, Spain.

BACKGROUND Deregulated expression/activation of transcription factors is a key event in the establishment and progression of human cancer. Furthermore, most oncogenic signaling pathways converge on sets of transcription factors that ultimately control gene expression patterns resulting in cancer development, progression, and metastasis. METHODS Ductal pancreatic adenocarcinoma (PDA) is the main type of pancreatic cancer and the fourth leading cause of cancer mortality in the Western world. The early stage of the disease is characterized by pancreatic intraepithelial neoplasia lesions bearing mutations in the K-RAS proto-oncogene, which progress to malignant PDA by accumulating additional mutations in the tumor suppressor gene CDKN2A (p16) and in SMAD4 and TP53 transcription factors. The involvement of other signaling pathways in PDA development and progression is an active area of research which may help to clarify the critical steps of this devastating disease. RESULTS In this regard, several in vitro and in vivo data have demonstrated the contribution of the transcription factor c-Myc to pancreatic carcinogenesis although the molecular mechanisms are poorly understood. c-Myc is a proto-oncogene which has a pivotal function in growth control, differentiation and apoptosis and is known to act as a downstream transcriptional effector of many signaling pathways involved in these processes. It is regulated at multiple levels and its abnormal expression contributes to the genesis of many human tumors. CONCLUSIONS This review focuses on the role of c-Myc in pancreatic embryonic development and homeostasis as well as its involvement on pancreatic tumorigenesis. Evidences showing that c-Myc function is highly dose and cell context dependent, together with its recently demonstrated ability to reprogram somatic cells towards a pluripotent stem cell-like state, indicate that the role of c-Myc in pancreas pathophysiology might have been previously underscored.

UI MeSH Term Description Entries
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090063 Proto-Oncogene Mas A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR. C-Mas Protein,II-Proto-Oncogene Proteins, Cellular,Mas Protein,Mas1 Protein,Proto-Oncogene Protein Mas,Proto-Oncogene Proteins C-Mas-1,C Mas Protein,C-Mas-1, Proto-Oncogene Proteins,Cellular II-Proto-Oncogene Proteins,II Proto Oncogene Proteins, Cellular,Mas, Proto-Oncogene,Protein Mas, Proto-Oncogene,Protein, C-Mas,Protein, Mas,Protein, Mas1,Proteins, Cellular II-Proto-Oncogene,Proto Oncogene Mas,Proto Oncogene Proteins C Mas 1
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D016259 Genes, myc Family of retrovirus-associated DNA sequences (myc) originally isolated from an avian myelocytomatosis virus. The proto-oncogene myc (c-myc) codes for a nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Truncation of the first exon, which appears to regulate c-myc expression, is crucial for tumorigenicity. The human c-myc gene is located at 8q24 on the long arm of chromosome 8. L-myc Genes,N-myc Genes,c-myc Genes,myc Genes,v-myc Genes,L-myc Proto-Oncogenes,N-myc Proto-Oncogenes,c-myc Proto-Oncogenes,myc Oncogene,v-myc Oncogenes,Gene, L-myc,Gene, N-myc,Gene, c-myc,Gene, myc,Gene, v-myc,Genes, L-myc,Genes, N-myc,Genes, c-myc,Genes, v-myc,L myc Genes,L myc Proto Oncogenes,L-myc Gene,L-myc Proto-Oncogene,N myc Genes,N myc Proto Oncogenes,N-myc Gene,N-myc Proto-Oncogene,Oncogene, myc,Oncogene, v-myc,Oncogenes, myc,Oncogenes, v-myc,Proto-Oncogene, L-myc,Proto-Oncogene, N-myc,Proto-Oncogene, c-myc,Proto-Oncogenes, L-myc,Proto-Oncogenes, N-myc,Proto-Oncogenes, c-myc,c myc Genes,c myc Proto Oncogenes,c-myc Gene,c-myc Proto-Oncogene,myc Gene,myc Oncogenes,v myc Genes,v myc Oncogenes,v-myc Gene,v-myc Oncogene
D016271 Proto-Oncogene Proteins c-myc Basic helix-loop-helix transcription factors encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis. L-myc Proteins,N-myc Proteins,c-myc Proteins,myc Proto-Oncogene Proteins,p62(c-myc),Proto-Oncogene Products c-myc,Proto-Oncogene Proteins myc,myc Proto-Oncogene Product p62,p62 c-myc,L myc Proteins,N myc Proteins,Proteins myc, Proto-Oncogene,Proto Oncogene Products c myc,Proto Oncogene Proteins c myc,Proto Oncogene Proteins myc,Proto-Oncogene Proteins, myc,c myc Proteins,myc Proto Oncogene Product p62,myc Proto Oncogene Proteins,myc, Proto-Oncogene Proteins,p62 c myc
D021441 Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS. Pancreatic Ductal Carcinoma,Carcinoma, Ductal, Pancreatic,Duct-Cell Carcinoma of the Pancreas,Duct-Cell Carcinoma, Pancreas,Ductal Carcinoma of the Pancreas,Pancreatic Duct Cell Carcinoma,Carcinoma, Pancreas Duct-Cell,Carcinomas, Pancreas Duct-Cell,Carcinomas, Pancreatic Ductal,Duct Cell Carcinoma of the Pancreas,Duct Cell Carcinoma, Pancreas,Duct-Cell Carcinomas, Pancreas,Ductal Carcinoma, Pancreatic,Ductal Carcinomas, Pancreatic,Pancreas Duct-Cell Carcinoma,Pancreas Duct-Cell Carcinomas,Pancreatic Ductal Carcinomas

Related Publications

Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
May 2024, Cancer medicine,
Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
February 2020, Oncology letters,
Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
May 2021, Gut,
Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
March 2021, Diagnostics (Basel, Switzerland),
Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
July 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
June 2007, Scandinavian journal of gastroenterology,
Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
December 2012, Gut,
Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
January 2023, Epigenomics,
Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
June 2023, Journal of clinical medicine,
Anouchka Skoudy, and Inmaculada Hernández-Muñoz, and Pilar Navarro
September 2018, Journal of experimental & clinical cancer research : CR,
Copied contents to your clipboard!